Navigation

Retired Compendial Notices

<1>: Proposed Revisions to the Labeling on Ferrules and Cap Overseals Section of General Chapter <1> Injections (posted 24–Nov–09)
<1> Injections, Labeling of Ferrules and Cap Overseals Section (posted 4–Aug–2010)
<1> Injections: Notice of Intent to Revise (posted 29–Jul–2009)
<1> Injections—USP Announcement on Labeling on Ferrules and Cap Overseals Section (posted 08–May–2009)
<1>: First Supplement to USP 31–NF 26 includes an incorrect General Chapter: <1> Injections (posted 07–Apr–2008)
<3>: USP Has Revised New General Chapter <3> Topical and Transdermal Drug Products: Quality Tests; To Be Republished in PF 36(6) (posted 20–Sep–2010)
<3> and <725> Topical and Transdermal Products—USP Forwards Proposed General Chapters on Topical and Transdermal Drug Products (posted 29–May–2009)
<17>: USP Seeks Comments on Proposed General Chapter <17> Prescription Container Labeling (posted 03–Jan–2011)
<17> Recommendations on Prescription Container Labeling (posted 26–Apr–2010)
<55> Second Supplement to USP 31–NF 26 Online and CD includes an incorrect version of USP General Chapter <55> Biological (posted 23–Jul–2008)
<61> and <62>: First Supplement USP 31–NF 26 included three errors in USP General Chapters <61> and <62> (posted 15–Aug–2008)
<81> Antibiotics—Microbial Assays: USP Proposes Revisions in PF 365 (posted 27–Aug–2010)
<381> Elastomeric Closures for Injections—Error in USP 32–NF 27 Publication Dates (posted 03–Dec–2008)
<467> Residual Solvents/Organic Volatile Impurities (posted 15–Jun–2007)
<643> Total Organic Carbon Comment Period Extension (posted 17–Oct–2007)
<711> Dissolution: Notice of Intent to Revise (posted 11–Mar–2008)
<725> and <3> Topical and Transdermal Products–USP Forwards Proposed General Chapters on Topical and Transdermal Drug Products (posted 29–May–2009)
<797>: Errata Corrected in Revised General Chapter <797> (posted 28–Jan–2008)
<823> Radiopharmaceuticals for Positron Emission Tomography–Compound: Notice of Intent to Revise (posted 24–Nov–2010)
<905> Uniformity of Dosage Units (posted 20–Apr–2007)
<1066> Physical Environments that Promote Safe Medication Use: Notice of Intent to Revise (posted 30–Apr–2010)
<1121> Nomenclature: Monograph Naming Policy for Salt Drug Substances in Drug Products and Compounded Preparations (posted 04–Jun–2007; official 01–May–2013)
<1151> Pharmaceutical Dosage Forms (posted 06–Oct–2009)
Acitretin Capsules (posted 22–Jul–2009)
Alendronate Sodium Tablets: Notice of Intent to Revise (posted 01–Feb–2008)
Amoxicillin and Clavulanate Potassium for Oral Suspension: Notice of Intent to Revise (posted 23–Nov–2011)
Cephalexin Monographs (posted 07–Dec–2009; revised 30–Jun–2010)
Changes to the Dissolution Performance Verification Test (posted 20–Nov–2009)
Coordination of Official New Monographs, Revisions, and USP Reference Standards (posted 20–Feb–2006)
Coordination of PF Submissions and New USP Reference Standards (posted 03–Apr–2006)
Correction to Pharmacopeial Forum 34(2) (posted 07–Mar–2008)
Estradiol Vaginal Inserts (posted 07–Dec–2009)
First Prescription/Nonprescription Stakeholder Forum for 2010–2015 Cycle Enables Broader Participation (posted 08–October–2010)
Galantamine Tablets: Notice of Intent to Revise (Reposted) (posted 12–Jun–2009)
Galantamine Tablets (posted 01–Aug–2008)
Glacial Acetic Acid (posted 26–Mar–2010)
Green Tea Cautionary Labeling Update (posted 10–Apr–2009)
Heparin: Notice of Heparin Stage 2 Interim Revision Announcements (posted 24–Jun–2009)
Heparin and Enoxaparin Monographs: Stage 2 Web Postings Supersede Printed Monographs in USP 33–NF 28 (posted 22–Dec–2009)
Levalbuterol Hydrochloride (posted 29–May–2009)
Levothyroxine Sodium Tablets (posted 29–Aug–2008; official 03–Oct–2009)
Loratadine Oral Solution: Notice of Intent to Revise (posted 29–Oct–2010)
Missing Page Numbers in Auxiliary Information from Eight Chapters (posted 10–Sep–2008)
Nefazodone Hydrochloride (posted 20–Mar–2009)
New USP Reference Standards (posted 07–Mar–2007)
Norethindrone Acetate and Ethinyl Estradiol Tablets: Notice of Intent to Revise (posted 30–Jul–2010)
Oxycodone Hydrochloride: Notice of Intent to Revise (POSTPONEMENT) (posted 24–Sep–2010)
Prescription/Nonprescription Stakeholder Forum Date Announced (posted 06–Apr–2011)
Propofol Injectable Emulsion: Notice of Intent to Revise (posted 28–Jan–2011)
Prospective Harmonization (posted 09–Nov–2009)
Protamine Sulfate Monographs (posted 26–Feb–2010)
Recent Modifications to the USP Standards–Setting Process (posted 17–Jul–2007)
Revision to USP Pending Monographs Guideline (posted 30–Jul–2010)
Revision to USP Pending Monographs Guideline (posted 30–Apr–2010)
Revision to USP Pending Monographs Guideline (posted 09–Nov–2009)
Six-Month Implementation Guideline
Sodium Fluoride and Acidulated Phosphate Topical Solution: Notice of Intent to Revise (posted 07–Mar–2007)
Tamsulosin Hydrochloride Capsules: Notice of Intent to Revise (posted 30–Apr–2010)
Tamsulosin Hydrochloride Capsules: Notice of Intent to Revise (posted 08–Apr–2009)
Tazobactam: Notice of Intent to Revise (posted 28–Jan–2011)
Tazobactam: Notice of Intent to Revise (posted 29–Feb–2008)
USP 32–NF 27 Commentary Amended (posted 19–Mar–2009)
USP 33–NF 28 Errata (posted 17–Nov–09)
USP Invites Public Comments on its Dietary Supplement Safety Review Process (posted 03–Dec–2008)
USP Releases Improved Packaging for Salicylic Acid Calibrator Tablets (posted 19–Oct–2005)
USP Revised Admission Criteria and Safety Classification for Dietary Supplements (posted 10–Apr–2009)
USP Revises its Request for Revision Guideline (posted 24–July–2009)
USP Statement on Prednisone Tablets: Notice of Change in Performance (posted 10–Oct–2007)
Vincristine Sulfate Monographs–USP Seeks Advice on Official Date: Notice of Intent to Revise (posted 30–Apr–2010)